1000 Mylan Blvd
78 articles about Viatris
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
1/2/2024Iovance’s lifileucel for advanced melanoma and Madrigal’s resmetirom for nonalcoholic steatohepatitis are just a couple of the key decisions on the FDA's docket this quarter.
Viatris, a global healthcare company, announced that it has packed 1,000 backpacks in partnership with Comfort Cases, a nonprofit organization that provides comfort and personal care items for children entering the foster care system.
Viatris Inc., a global healthcare company, announced the company will participate in the Jefferies London Healthcare Conference in London, UK on Wednesday, November 15, 2023.
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Viatris Inc., a global healthcare company, and Theravance Biopharma, Inc. announced positive results from the YUPELRI® Phase III placebo-controlled clinical trial conducted in China assessing the efficacy and safety of YUPELRI, a once-daily nebulized long-acting muscarinic antagonist for the maintenance treatment of patients with COPD.
Viatris Inc., a global healthcare company, announced that its President, Rajiv Malik, will be retiring as an executive of the Company effective April 1, 2024.
Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc.
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc.
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
Viatris Inc. announced it has received an offer for the divestiture of substantially all of its Over-the-Counter business, and has entered into definitive agreements to divest its Women's Healthcare business, its Active Pharmaceutical Ingredients business in India and commercialization rights in certain non-core markets that were acquired as part of the Upjohn Transaction.
The companies on Wednesday secured the regulator’s approval for their eye drop Ryzvumi for the reversal of pharmacologically-induced mydriasis, as Viatris looks to add $1 billion in sales by 2028.
Viatris Inc. and Ocuphire Pharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI™.
Viatris Inc., a global healthcare company, announced that it has been named to TIME's World's Best Companies 2023 list.
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
Viatris Inc., a global healthcare company, announced U.S. Food and Drug Administration tentative approval for a New Drug Application for abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients.
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
Viatris Inc., a global healthcare company, and Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for review the companies' recently submitted New Drug Application for GA Depot 40 mg.
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges
Viatris Inc. (NASDAQ: VTRS) today reported another strong quarter of operating results which continues to set the Company up well as it prepares to bring its Phase 1 strategy to an end and position itself for a strong beginning of Phase 2 in 2024 and beyond.
Viatris Inc. (NASDAQ: VTRS) plans to report its second quarter 2023 financial results on Monday, August 7 before the open of the U.S. financial markets.
Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year
Viatris Inc. Robert J. Coury will once again transition his role, this time from his current position of Executive Chairman to Chairman Emeritus and Senior Strategic Advisor to the board and management following the company's 2023 annual meeting of shareholders.
Viatris Inc. today announced that as part of its ongoing board refreshment efforts, Leo Groothuis has been appointed as Viatris' newest member of its board of directors.
Viatris Inc. ( NASDAQ : VTRS ), a global healthcare company, today announced the company will participate in the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on Tuesday, June 13, 2023.
Viatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine
Viatris Inc. published its 2022 Sustainability Report showcasing its commitment, impact and progress on building sustainable access to medicine as it continues to make a positive difference across key areas including Access and Global Health, Our People, the Environment and the Community.
Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges
Viatris Inc. (NASDAQ: VTRS) today reported strong results for the first quarter of 2023 reflecting another robust operational performance and instilling further confidence in the Company's ability to return to growth as it prepares to enter Phase 2 of its strategic plan in 2024.